Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this research is investigating the heart rate changes in schizophrenic and bipolar patients under the medication of aripiprazole and quetiapine. In the mean time, we are hoping further investigating the interrelationship of medicine dosage and heart rate change, in order to acquire the best relationship both effectiveness as well as safety in acceptable heart rate change of clinical suggestion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics

NCT00689325

Schizophrenia

COMPLETED

Fast Titration in the Treatment of Schizophrenia, Taiwan

NCT00304473

Schizophrenia

COMPLETED PHASE3

A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine

NCT00791622

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE1

Effect of Quetiapine on Negative Symptoms and Cognition

NCT00305422

Schizophrenia

COMPLETED PHASE3

Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients

NCT00951483

Depression Anxiety

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Goal: The goal of this research is investigating the heart rate changes in schizophrenic and bipolar patients under the medication of aripiprazole and quetiapine. As we known, clozapine, an antipsychotic, could cause fatal cardiac arrhythmia; in previous reports showed fatal rate about 0.7%, in spite of not very high, it reflects heart rate change decreasing. Therefore, many researches begin to focus on the relationship and heart rate change. Quetiapine, an atypical antipsychotic, FDA approved in 1997, Department of Health (DOH) in Taiwan also approved for schizophrenia for its effectiveness of negative disorders, low extrapyramidal syndrome, low side-effects of muscle catatonia and sluggishness. The side-effects of quetiapine are lethargy, nausea (occur rate 9%-44%), insomnia (12%), postural hypotension (4%-7%), constipation(8-10%), thirsty (9%-44%), weight gain (5-23%) and liver enzyme (GGT、AST、ALT) increasing (6%). Aripiprazole, FDA approved in 2002, DOH in Taiwan also approved for schizophrenia for its effective remittance of positive disorders, also effective for negative disorders and cognitive function regression. Besides, aripiprazole combine lithium or valproic acid can control the onset of manic and mixure of bipolar patients. The side-effects of aripiprazole are few, low extrapyramidal syndrome, no significant weight gain and blood sugar level, not surge in prolactin level and low menstrual cycle abnormal, gynecomastia and sexual dysfunction. Other side-effects are postural hypotension (0.6%-4%), headache (12%-27%), lethargy (8%-18%), insomnia (5%-26.3%), constipation (5-11%). Both quetiapine and aripiprazole are atypical antipsychotic, serious side-effects are fewer than typical antipsychotics, however, in some sensitive patients still have some side-effects such as limb-stiffness and akathisia (quetiapine 4%-12%, aripiprazole 2%-27.3%). In some retrospect researches, quetiapine will increase the opportunity of cardio- sudden death and pass off by 0.3%-1% in age 30-74 adult. On the other hand, aripiprazole (0.1%-1%) showed prolonging of QT wave which was considered as a danger factor of fatal arrhythmia. Despite of the danger, serious side-effects are rare, aripiprazole and quetiapine are widely used in clinical.

This study hope to further study whether quetiapine and aripiprazole will occur heart rate changes similar to clozapine, using heart rate changes approach to find out the possibility of causing arrhythmia and fatal of these 2 medicines.

Secondary goal:

1. Further investigate the relationship of drug dosage and heart rate change, in order to acquire the best relationship both effectiveness as well as safety in acceptable heart rate change of clinical suggestion.
2. The subjects of this study are schizophrenic and bipolar patients, who use quetiapine and aripiprazole, also will stratify into gender, age and influence of heart rate changes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Bipolar

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aripipazole

Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication

Group Type ACTIVE_COMPARATOR

Aripiprazole; Quetiapine

Intervention Type DRUG

Aripiprazole Quetiapine

Quetiapine

Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication

Group Type ACTIVE_COMPARATOR

Aripiprazole; Quetiapine

Intervention Type DRUG

Aripiprazole Quetiapine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aripiprazole; Quetiapine

Aripiprazole Quetiapine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age between 20 to 50, all genders.
2. Psychiatry doctor diagnosed who met DSM-IV-TR criteria schizophrenia or bipolar patients and using antipsychotics.
3. Psychiatry doctor first diagnosed who met DSM-IV-TR criteria schizophrenia or bipolar patients and without using antipsychotics.
4. Participants understand the goal of this experiment and willing to cooperate for evaluating heart rate change measurement. Participants need to understand the procedure of this study.
5. Participants voluntarily join this interview, approximately 30-45min.
6. Clinical reviewed patient's condition need to use quetiapine or aripiprazole.

Control group

1. Age between 20 to 50, all genders.
2. Psychiatry doctor diagnosed who exclude DSM-IV-TR schizophrenia or bipolar patients.
3. Participants understand the goal of this experiment and willing to cooperate for evaluating heart rate change measurement. Participants need to understand the procedure of this study.
4. Participants voluntarily join this interview, approximately 30-45min.

3. Participants have cardio-vascular disease, diabetes, hepatic cirrhosis, kidney disease, material abuser (smoking not excluded) and long-term-effective psychotics user.
4. Participant has combination diseases, it could seriously influence diagnosis.
5. Psychopathy or psychosis can not be categorized in defined group.
6. Clinical reviewed patient's condition need to switch other medicine.
7. Clinical reviewed patient's condition need to quite this experiment and record reasons.
8. Participants decide to quite experiment without any conditions.

Control group

1. Participants fail to understand the goal of this experiment and unwilling to cooperate for evaluating heart rate change measurement.
2. Participants have cardio-vascular disease, diabetes, hepatic cirrhosis, kidney disease, material abuser (smoking not excluded) and long-term-effective psychotics user.
3. Participants decide to quite experiment without any conditions.

Exclusion Criteria

Experimential Group:

1. Participants fail to understand the goal of this experiment and unwilling to cooperate for evaluating heart rate change measurement.

Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes